Harvard Bioscience, Inc. (HBIO), a provider of specialized life-science research instruments, announced for a 1-for-10 reverse stock split that will take effect on March 13, 2026, with split-adjusted trading beginning March 16, 2026.
Following the announcement HBIO shares fell roughly 12% in overnight trading, extending Friday's decline.
Under the split, every 10 existing shares will be consolidated into a new share, reducing the outstanding share count from roughly 44.7 million to 4.47 million. Harvard Bioscience noted that the reverse split does not change the total number of authorized shares. The company will also make proportional adjustments to outstanding stock options, warrants, convertible securities, and equity incentive plans.
The company is schedules to report its fourth-quarter financial results on March 12, 2026, ahead of market open.
HBIO has traded between $0.28 and $0.95 over the past year. The stock closed Friday's (March 6, 2026) trading at $0.55, down 3.68%. During the overnight trading session, the stock slipped to $0.47, down 12.76%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.